Schizophrenia is a major neurologic illness with an impact on public h
ealth that has been unappreciated. Newer and arguably move effective m
edication treatments are now available and hold considerable premise.
The higher up-front cost of these drugs is, on current evidence, offse
t by other economic advantages and, from a humanitarian perspective, b
y the expectation of improved patient outcome with less drug toxicity.
The extent to which these drugs replace older drug treatments will be
determined by the relative influences of clinical, pharmacoeconomic,
mental health administrative, and advocacy factors over the coming yea
rs.